V-Wave’s Post

Congratulations to Babson Diagnostics for being named Medtech Company of the Year by both MD+DI Editors and Readers!! This sampling of survey comments by readers really sums it up: - Great mission, doing things that others couldn't - #Groundbreaking technology and legitimate capillary testing could be a game changer for patients - #Accessibility. I wish this had been in place when I had to continually take my mom to labs for bloodwork. - Making routine blood testing more accessible and #convenient will have a profound impact on the entire #healthcare system. They achieved commercial readiness and launch this year, and clinicians and providers all rave about the experience so far. - Potential massive impact in cost and convenience Truly exciting, game-changing work underway! Editors' Choice announcement: https://lnkd.in/eCSUg9tu Readers' Choice announcement: https://lnkd.in/e-JJCpwn #VC #patientcare #innovation #BackedByEmerald #patientexperience #changetheworld

Haemonetics to sell whole blood assets to GVS for $67.1 million https://lnkd.in/dkpaarUm Haemonetics Corporation, a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced that it has entered into a definitive agreement to sell its whole blood assets to GVS, S.p.A (GVS) ... Published by https://www.pharmabiz.com/

Johnson & Johnson (J&J) is strengthening its medtech portfolio with the US $13.1B acquisition of Shockwave Medical. This deal integrates Shockwave’s cutting-edge intravascular lithotripsy (IVL) technology, which treats calcified coronary arteries. Read more: https://lnkd.in/d55Nmc5x #JohnsonAndJohnson #ShockwaveMedical #MedTech #CardiovascularHealth #IVLTechnology #HealthcareInnovation #MergersAndAcquisitions #MedicalDevices

Johnson & Johnson announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech. Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally. We are delighted to welcome the Shockwave team to Johnson & Johnson and look forward to bringing their innovative IVL technology to more patients around the world.” Tim Schmid, Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech, said, “Completing this acquisition is a significant milestone in the expansion of our leadership position in the medtech industry. Shockwave’s differentiated solutions and robust pipeline represent an exciting opportunity for Johnson & Johnson MedTech to bring more innovations to patients in one of the largest areas of unmet medical need. We are excited to begin collaborating directly with the Shockwave team and look forward to a bright future together.” This transaction further extends Johnson & Johnson MedTech’s leadership in cardiovascular intervention. Shockwave offers the first and only commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD) and complements Johnson & Johnson’s leading positions in heart recovery (Abiomed) and electrophysiology (Biosense Webster) to make it a category leader in four of the largest and highest-growth medtech markets within cardiovascular intervention. Shockwave is ultimately expected to become Johnson & Johnson MedTech’s thirteenth priority platform, as defined by annual sales of at least $1 billion. The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech. Johnson & Johnson expects the transaction to be accretive to operating margin, but considering the impact of financing costs, is expected to dilute adjusted earnings per share by approximately $0.10 in 2024 and approximately $0.17 in 2025. In connection with the completion of the transaction, Shockwave’s common stock ceased trading on NASDAQ. #intravascularlithotripsy #cardiovascularintervention #acquisition #Shockwave #JohnsonandJohnson #JnJ #MedTech #JNJMedTech #JNJMedTechProud 

Johnson & Johnson MedTech & Johnson just submitted Ottava for FDA IDE and beat Wall Street expectations in Q3! Johnson & Johnson (NYSE: JNJ) had an eventful third quarter, showcasing both financial strength and innovation in the MedTech sector. Shares saw a slight pre-market dip but recovered quickly, climbing by 1% to settle at $163.10. One of the significant milestones is the submission of their Ottava surgical robot for FDA investigational device exemption (IDE). This long-awaited development promises to bring unparalleled flexibility and control to robotic-assisted surgeries. The financials were also impressive. J&J reported profits of $2.7 billion on sales of $22.47 billion, surpassing Wall Street predictions. The MedTech unit alone recorded $7.9 billion in sales, driven by strong performances in electrophysiology, cardiovascular units, and other key areas. J&J's commitment to innovation is apparent not just from the Ottava submission but also from new product launches like the Velys Spine and Shockwave Medical E8 IVL catheter. Drop a comment or visit www.rinconsearchgroup.com. #MedTech #Innovation #JohnsonAndJohnson

Johnson & Johnson has agreed to #acquire Israeli #medtech firm V-Wave in a deal that could reach $1.7 billion! 🔬 This strategic move includes a $600M upfront payment, with potential additional payments contingent on regulatory and commercial milestones. V-Wave's Ventura Interatrial Shunt System, which targets heart failure with reduced ejection fraction, is a key #innovation in J&J's expanding #cardiovascular portfolio. 🚀 This #acquisition underscores J&J's commitment to transforming heart health #globally. 🌏 🔗Read More - https://lnkd.in/dQwMhrr5 🖊️Writes - Dr. Jayati Dubey 🌐Stay Informed with our Latest Stories – https://lnkd.in/gMUPB2Zp 📌 DHN HealthTech Innovation Challenge 2024 is here, Submit your application today -https://dhninnovation.com/   #JohnsonAndJohnson #MedTech #HeartHealth #Innovation #VWave #CardiovascularCare #HealthcareInnovation #MedicalDevices

𝐌𝐞𝐝𝐭𝐫𝐨𝐧𝐢𝐜 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 (2011-2023)   Historically Medtronic reported its revenue with the following breakdown: 1- Cardiovascular 2- Restorative Therapies   The flowing are some of the highlights of #Medtronic over the years.   2011: Omar Ishrak becomes the new CEO and Chairman of Medtronic. During his time, he doubles Medtronic's revenue and valuation. 2013: Medtronic separates “Diabetes” from “Restorative Therapies” and turns it into a stand-alone division. 2014: Medtronic acquires Covidien (Medtronic Minimally Invasive Therapies Group) for $42.9B. After the acquisition, Medtronic adds “Minimally Invasive Therapies” to its revenue breakdown. Today Covidien accounts for roughly one-third of Medtronic's revenue. 2016: Medtronic becomes top #medicaldevice company by revenue. To this date, Medtronic maintains this position. 2020: Geoff Martha becomes the new CEO and Chairman of Medtronic. 2020: Medtronic changes its “Minimally Invasive Therapies” division to “Medical Surgical” and “Restorative Therapies” to “Neuroscience”.   Today Medtronic breaks down its revenue ($31.2B) into the following four divisions: 1. Cardiovascular ($11.6B), 2. Medical-Surgical ($8.4B), 3. Neuroscience ($9B) 4. Diabetes ($2.3B).   Over the last few years, Medtronic has shown steady growth in almost all its divisions. The acquisition of #Covidien has also proved to be very successful. In addition to the Top-line growth, Medtronic has also shown a steady increase in its bottom line, thanks to its strong economics. Today, Medtronic is the top medical device company by revenue followed by Johnson & Johnson MedTech and Siemens Healthineers.   The combination of having the highest revenue and high profit margin has made Medtronic one of the most valued medical companies. Today Medtronic has a market cap comparable to that of Siemens Healthineers, GE HealthCare, and Philips combined ($110B vs $65B + $40B + $20B). Would be interesting to see if Medtronic can maintain its top position in coming years.

📈 The MedTech Sprint Continues! ⚡ Boston Scientific, Dexcom, and Edwards Lifesciences are on the starting blocks to share their Q1 feats this week. 🏁 Last week, J&J, Abbott, and Intuitive Surgical set a brisk pace with robust volumes 🌍. The buzz now? It's Farapulse by Boston Scientific - a game-changer in the PFA domain with eyes peeled for their market rivalry with Medtronic 👀. Dexcom's up Thursday, chasing Abbott's 20% jump in CGM sales. With the G7 device's traction and a looming OTC CGM breakthrough, Stelo, growth prospects look sweet. 📊📈 Closing the week, Edwards Lifesciences awaits the TAVR market pulse post-Medtronic's trial buzz. With a steady TAVR demand, will they meet their high bar of 8-10% growth? ⏳ As always, it's about innovation, market position, and the bold steps shaping HealthTech's future. Any thoughts on these impending updates? Drop a comment, let's chat! 👇 #MedTech #Earnings #HealthTechInnovation

Some acquisition news with J&J! 📣 Please take a moment today to check out this article. It is an exciting read about Johnson & Johnson's agreement to acquire Shockwave Medical. https://lnkd.in/g6faRxrU

Johnson & Johnson Concludes Acquisition Of Shockwave Medical Johnson & Johnson has announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech. Shockwave is ultimately expected to become Johnson & Johnson MedTech’s thirteenth priority platform, as defined by annual sales of at least $1 billion. The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech. Johnson & Johnson expects the transaction to be accretive to operating margin, but considering the impact of financing costs, is expected to dilute adjusted earnings per share by approximately $0.10 in 2024 and approximately $0.17 in 2025. In connection with the completion of the transaction, Shockwave’s common stock ceased trading on NASDAQ. Joaquin Duato Tim Schmid #johnsonandjohnson #johnsonandjohnsonnews #acquisition #shockwavemedical